Harvard Bioscience Profit Margin 2012-2026 | HBIO
Current and historical gross margin, operating margin and net profit margin for Harvard Bioscience (HBIO) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Harvard Bioscience net profit margin as of March 31, 2026 is -65.51%.
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Computer and Technology | Scientific Instruments Manufacturing | $0.019B | $0.087B |
| HARVARD BIOSCIENCE develops, manufactures and markets tools used in drug discovery research at pharmaceutical and biotechnology companies, universities and government laboratories. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Bruker (BRKR) | United States | $5.722B | 20.54 |
| Kewaunee Scientific (KEQU) | United States | $0.100B | 8.24 |